Preemptive Therapy With Venetoclax for High Risk Chronic Lymphoid Leukemia Stage A Patients, a Phase II Trial of the FILO
Phase of Trial: Phase II
Latest Information Update: 24 Jun 2019
Price : $35 *
At a glance
- Drugs Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Acronyms PREVENE
- 19 Jun 2019 Status changed from not yet recruiting to recruiting.
- 29 Apr 2019 Planned initiation date changed from 1 Feb 2019 to 15 May 2019.
- 23 Jan 2019 Planned End Date changed from 1 Jan 2028 to 1 Feb 2028.